Neuronetics (STIM) said Friday it priced its previously announced public offering of eight million shares at $2.25 per share, raising about $18 million in gross proceeds.
The company also granted the underwriter a 30-day option to purchase an additional 1.2 million shares.
Proceeds from the offering, expected to close on Feb. 10, will be used for various corporate purposes, including sales, marketing, R&D, potential acquisitions, inventory, and capital expenditures.
Shares of the company fell 32% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.